Literature DB >> 22366643

Glucose-dependent insulinotropic peptide impairs insulin signaling via inducing adipocyte inflammation in glucose-dependent insulinotropic peptide receptor-overexpressing adipocytes.

Yaohui Nie1, Ronald C Ma, Juliana C N Chan, Haiyan Xu, Gang Xu.   

Abstract

Glucose-dependent insulinotropic peptide (GIP) exerts multiple biological effects via the G-protein-coupled receptor GIPR, including glucose-stimulated insulin production and secretion, cell proliferation, and antiapoptosis in pancreatic β-cells. In an obese state, the circulating level of GIP is elevated. GIPR-knockout mice are resistant to high-fat-diet-induced obesity. The rising evidence suggests a potential role of GIP in adipocyte biology and lipid metabolism. In our study, we overexpressed GIPR in 3T3-L1 CAR adipocytes and demonstrated that GIP impaired the physiological functions of adipocytes as a consequence of increased production of inflammatory cytokines and chemokines and phosphorylation of IkB kinase (IKK)-β through activation of the cAMP-PKA pathway. Activation of Jun N-terminal kinase (JNK) pathway was also observed during GIP-induced inflammatory responses in adipocytes. The inhibition of JNK blocked GIP-stimulated secretion of inflammatory cytokines and chemokines, as well as phosphorylation of IKKβ. In addition, GIP-induced inflammatory response increased basal glucose uptake but inhibited insulin-stimulated glucose uptake. Moreover, GIP-induced adipocyte inflammation impaired insulin signaling in adipocytes as demonstrated by a reduction of AKT phosphorylation. Our results suggest that GIP might be one of the stimuli attributable to obesity-induced insulin resistance via the induction of adipocyte inflammation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22366643     DOI: 10.1096/fj.11-196782

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  17 in total

1.  Gut Hormone GIP Induces Inflammation and Insulin Resistance in the Hypothalamus.

Authors:  Yukiko Fu; Kentaro Kaneko; Hsiao-Yun Lin; Qianxing Mo; Yong Xu; Takayoshi Suganami; Peter Ravn; Makoto Fukuda
Journal:  Endocrinology       Date:  2020-09-01       Impact factor: 4.736

2.  Pro-inflammatory gene expression profile in obese adults with high plasma GIP levels.

Authors:  J Góralska; U Raźny; A Polus; J Stancel-Możwiłło; M Chojnacka; A Gruca; A Zdzienicka; A Dembińska-Kieć; B Kieć-Wilk; B Solnica; M Malczewska-Malec
Journal:  Int J Obes (Lond)       Date:  2017-12-13       Impact factor: 5.095

3.  Regulation of the pro-inflammatory cytokine osteopontin by GIP in adipocytes--a role for the transcription factor NFAT and phosphodiesterase 3B.

Authors:  Bilal Omar; Elin Banke; Emilia Guirguis; Lina Åkesson; Vincent Manganiello; Valeriya Lyssenko; Leif Groop; Maria F Gomez; Eva Degerman
Journal:  Biochem Biophys Res Commun       Date:  2012-08-07       Impact factor: 3.575

Review 4.  Type 2 diabetes mellitus: From a metabolic disorder to an inflammatory condition.

Authors:  Iqra Hameed; Shariq R Masoodi; Shahnaz A Mir; Mudasar Nabi; Khalid Ghazanfar; Bashir A Ganai
Journal:  World J Diabetes       Date:  2015-05-15

5.  Effect of troxerutin on insulin signaling molecules in the gastrocnemius muscle of high fat and sucrose-induced type-2 diabetic adult male rat.

Authors:  Sathish Sampath; Balasubramanian Karundevi
Journal:  Mol Cell Biochem       Date:  2014-06-01       Impact factor: 3.396

Review 6.  The role of gastrointestinal hormones in hepatic lipid metabolism.

Authors:  Jamie Eugene Mells; Frank A Anania
Journal:  Semin Liver Dis       Date:  2013-11-12       Impact factor: 6.115

7.  Association between dietary phylloquinone intake and peripheral metabolic risk markers related to insulin resistance and diabetes in elderly subjects at high cardiovascular risk.

Authors:  Martí Juanola-Falgarona; Jordi Salas-Salvadó; Ramon Estruch; Maria P Portillo; Rosa Casas; Jonatan Miranda; Miguel A Martínez-González; Mònica Bulló
Journal:  Cardiovasc Diabetol       Date:  2013-01-08       Impact factor: 9.951

8.  Incretin action on bone: An added benefit?

Authors:  Ronald C W Ma; Gang Xu
Journal:  J Diabetes Investig       Date:  2014-09-15       Impact factor: 4.232

9.  Pharmacological reduction of NEFA restores the efficacy of incretin-based therapies through GLP-1 receptor signalling in the beta cell in mouse models of diabetes.

Authors:  Z F Kang; Y Deng; Y Zhou; R R Fan; J C N Chan; D R Laybutt; J Luzuriaga; G Xu
Journal:  Diabetologia       Date:  2012-11-28       Impact factor: 10.122

Review 10.  Estrogen Deficiency and the Origin of Obesity during Menopause.

Authors:  Fernando Lizcano; Guillermo Guzmán
Journal:  Biomed Res Int       Date:  2014-03-06       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.